Recruiting

Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical Trial

This study evaluates whether a digital patient education program can improve adherence to KDIGO 2022 dietary recommendations (low sodium and optimal protein intake) among patients with type 2 diabetes and chronic kidney disease (eGFR 30-59 ml/min).

ClinicalTrials.gov IDNCT07485075

PhaseNA

Enrollment104

SponsorSteno Diabetes Center Copenhagen

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Diabetes Type 2, Kidney Disease

About this study

Interventions

Device: StenoFood App — Digital patient education program (app-based) with dietary guidance and self-monitoring tools

Primary outcomes

Change in sodium excretion between measurements at baseline and 6 months follow-up (6 month)

Eligibility information

Inclusion Criteria: * Type 2 diabetes (ICD-10 DE11.x) * Age 18-74 years * BMI \< 35 kg/m² * eGFR 30-59 ml/min and UACR \> 30 mg/g * Stable medication for ≥3 months * Ability to read and understand Danish Exclusion Criteria: * Type 1 diabetes or other diabetes types * Current vegan diet * Active cancer * Short bowel syndrome or celiac disease * Use of sodium chloride tablets * No access to digital platform (intervention group only)

Study locations

Steno Diabetes Center Copenhagen,, Herlev, Captial Region of Denmark 2730 Denmark
Nordsjællands Hospital, Hillerød, Hillerød, Captial Region of Denmark 3400 Denmark

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.